Accolade Past Earnings Performance
Past criteria checks 0/6
Accolade's earnings have been declining at an average annual rate of -39.2%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 29.8% per year.
Key information
-39.2%
Earnings growth rate
29.7%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 29.8% |
Return on equity | -28.2% |
Net Margin | -31.6% |
Next Earnings Update | 25 Apr 2024 |
Recent past performance updates
Recent updates
Accolade: Staying Bullish On Favorable Developments
Apr 05Why We're Not Concerned About Accolade, Inc.'s (NASDAQ:ACCD) Share Price
Feb 17Accolade: Remain Confident That FY25 Guided Growth Is Achievable
Jan 17Accolade: Turning Bullish After Beat-And-Raise Quarter (Rating Upgrade)
Jan 11Why Investors Shouldn't Be Surprised By Accolade, Inc.'s (NASDAQ:ACCD) 27% Share Price Surge
Jun 13Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?
May 02An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued
Feb 05Accolade: Inching Closer To Profitability
Oct 17Accolade Q2 2023 Earnings Preview
Oct 05Accolade: Fair And Reasonably Priced, But Needs More Time
Aug 09Accolade Q1 2023 Earnings Preview
Jun 29Accolade: Little Recent Applause
Mar 28Accolade Impresses With Revenue Growth But Faces Operating Losses
Dec 16Accolade: I May Add To My Position
Oct 18Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets
Jul 11Accolade, Inc. 2021 Q4 - Results - Earnings Call Presentation
May 06Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation
Mar 19Is Accolade, Inc. (NASDAQ:ACCD) Popular Amongst Institutions?
Jan 15Accolade is up 7% on acquisition of 2nd.MD
Jan 14Accolade Inc.: Bullish Outlook As Its HealthTech Platform Helps Companies Save
Jan 12Accolade, Inc. 2021 Q3 - Results - Earnings Call Presentation
Jan 11Accolade Q3 2021 Earnings Preview
Jan 06Revenue & Expenses BreakdownBeta
How Accolade makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Nov 23 | 388 | -123 | 163 | 98 |
31 Aug 23 | 380 | -142 | 166 | 99 |
31 May 23 | 371 | -155 | 170 | 98 |
28 Feb 23 | 363 | -460 | 175 | 99 |
30 Nov 22 | 358 | -464 | 188 | 98 |
31 Aug 22 | 350 | -401 | 189 | 97 |
31 May 22 | 336 | -417 | 190 | 95 |
28 Feb 22 | 310 | -123 | 173 | 84 |
30 Nov 21 | 275 | -93 | 138 | 75 |
31 Aug 21 | 230 | -132 | 110 | 65 |
31 May 21 | 194 | -85 | 78 | 55 |
28 Feb 21 | 170 | -51 | 63 | 50 |
30 Nov 20 | 156 | -48 | 57 | 45 |
31 Aug 20 | 147 | -50 | 57 | 43 |
31 May 20 | 140 | -49 | 56 | 42 |
29 Feb 20 | 133 | -51 | 56 | 42 |
30 Nov 19 | 123 | -56 | 55 | 43 |
28 Feb 19 | 95 | -56 | 43 | 36 |
28 Feb 18 | 77 | -61 | 43 | 31 |
Quality Earnings: ACCD is currently unprofitable.
Growing Profit Margin: ACCD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACCD is unprofitable, and losses have increased over the past 5 years at a rate of 39.2% per year.
Accelerating Growth: Unable to compare ACCD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACCD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.1%).
Return on Equity
High ROE: ACCD has a negative Return on Equity (-28.23%), as it is currently unprofitable.